TG Therapeutics (TG Therapeutics) Interest Expense : $-12.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TG Therapeutics's interest expense for the three months ended in Dec. 2023 was $ -2.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TG Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -12.5 Mil. TG Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -2.4 Mil. TG Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TG Therapeutics Interest Expense Historical Data

The historical data trend for TG Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Interest Expense Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-5.29

-6.33

-5.64

-10.19

-12.62

TG Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-2.86	-2.84	-3.63	-3.71	-2.43

TG Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.6 Mil.

TG Therapeutics (NAS:TGTX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TG Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-2.4 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-12.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $109.3 Mil.

TG Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

TG Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

TG Therapeutics (TG Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NKB2:Germany NKB2:Germany

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Executives

Laurence N Charney	director	MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power	officer: CFO, Secretary and Treasurer	787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss	director, officer: CEO and President	750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial	director	C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard	director	C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume	director	3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy	director	C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u.	10 percent owner	3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum	director	787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc	10 percent owner	787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019